These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preventing post-ERCP pancreatitis: where are we? Testoni PA JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013 [TBL] [Abstract][Full Text] [Related]
3. Post-ERCP pancreatitis. Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323 [TBL] [Abstract][Full Text] [Related]
4. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786 [TBL] [Abstract][Full Text] [Related]
7. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959 [TBL] [Abstract][Full Text] [Related]
8. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015 [TBL] [Abstract][Full Text] [Related]
9. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917 [TBL] [Abstract][Full Text] [Related]
10. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts. Lee JK; Park JK; Yoon WJ; Lee SH; Lee KH; Ryu JK; Kim YT; Yoon YB J Clin Gastroenterol; 2007 Apr; 41(4):427-31. PubMed ID: 17413615 [TBL] [Abstract][Full Text] [Related]
11. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. Poon RT; Fan ST JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014 [TBL] [Abstract][Full Text] [Related]
12. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806 [TBL] [Abstract][Full Text] [Related]
13. Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done? Hauser G; Milosevic M; Stimac D; Zerem E; Jovanović P; Blazevic I World J Gastroenterol; 2015 Jan; 21(4):1069-80. PubMed ID: 25632179 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials. Chiu YJ; Chen SC; Kang YN; Hou SK; Chao CC; Chang CC J Formos Med Assoc; 2021 Apr; 120(4):1090-1099. PubMed ID: 33183879 [TBL] [Abstract][Full Text] [Related]
16. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. Lee TY; Choi JS; Oh HC; Song TJ; Do JH; Cheon YK Korean J Intern Med; 2015 Sep; 30(5):602-9. PubMed ID: 26354054 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665 [TBL] [Abstract][Full Text] [Related]
18. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632 [TBL] [Abstract][Full Text] [Related]